These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 26093132)

  • 1. [Pharmacogenetics: a promising tool to personalize immunosuppressive therapy in renal transplantation].
    Caletti C; Granata S; Tomei P; Dalla Gassa A; Lupo A; Zaza G
    G Ital Nefrol; 2015; 32(3):. PubMed ID: 26093132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine.
    Zaza G; Granata S; Tomei P; Dalla Gassa A; Lupo A
    Int J Mol Sci; 2015 Feb; 16(2):4281-305. PubMed ID: 25690039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunosuppression for kidney transplant recipients: current strategies].
    Alberú J; Urrea EM
    Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunosuppressive treatments: mechanisms of action and clinical use].
    Thervet E; Zuber J; Sberro R; Canaud G; Anglicheau D; Snanoudj R; Mamzer-Bruneel MF; Martinez F; Legendre C
    Nephrol Ther; 2011 Dec; 7(7):566-81. PubMed ID: 21273149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P; Ruggenenti P; Remuzzi G
    Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract]   [Full Text] [Related]  

  • 6. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen.
    Suwelack B; Malyar V; Koch M; Sester M; Sommerer C
    Transplant Rev (Orlando); 2012 Jul; 26(3):201-11. PubMed ID: 21940156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
    Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
    Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era.
    Colla L; Diena D; Rossetti M; Manzione AM; Marozio L; Benedetto C; Biancone L
    J Nephrol; 2018 Jun; 31(3):361-383. PubMed ID: 29476421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive drugs after solid organ transplantation.
    van Sandwijk MS; Bemelman FJ; Ten Berge IJ
    Neth J Med; 2013; 71(6):281-9. PubMed ID: 23956308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs.
    Pouché L; Stojanova J; Marquet P; Picard N
    Pharmacogenomics; 2016 Feb; 17(3):277-96. PubMed ID: 26799749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic monitoring of immunosuppressive drugs.
    Yatscoff RW; Langman LJ; LeGatt DF
    Transplant Proc; 1996 Dec; 28(6):3013-5. PubMed ID: 8962169
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunosuppressive treatment].
    Niaudet P
    Nephrol Ther; 2011 Dec; 7(7):592-8. PubMed ID: 22118788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.
    Thaunat O; Koenig A; Leibler C; Grimbert P
    J Am Soc Nephrol; 2016 Jul; 27(7):1890-900. PubMed ID: 26872489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of mammalian target of rapamycin inhibitors ab initio after liver transplantation without corticosteroids or induction therapy.
    Manzia TM; Angelico R; Toti L; Belardi C; Cillis A; Quaranta C; Tariciotti L; Katari R; Mogul A; Sforza D; Orlando G; Tisone G
    Dig Liver Dis; 2016 Mar; 48(3):315-20. PubMed ID: 26682720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evidences in immunosuppression in the maintenance of renal transplantation].
    Hernández D; González-Posada JM
    Nefrologia; 2005; 25(4):369-80. PubMed ID: 16231502
    [No Abstract]   [Full Text] [Related]  

  • 16. [Improved immunosuppression leads to better kidney transplantations].
    Ekberg H
    Lakartidningen; 2012 Sep 26-Oct 9; 109(39-40):1739-42. PubMed ID: 23097879
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of mTOR inhibitors in adult solid organ transplantation.
    Ventura-Aguiar P; Campistol JM; Diekmann F
    Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Guba M; Jauch KW
    N Engl J Med; 2008 Jun; 358(23):2518; author reply 2519-20. PubMed ID: 18525054
    [No Abstract]   [Full Text] [Related]  

  • 20. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.
    Guba M; Pratschke J; Hugo C; Krämer BK; Pascher A; Pressmar K; Hakenberg O; Fischereder M; Brockmann J; Andrassy J; Banas B; Jauch KW;
    Transpl Int; 2012 Apr; 25(4):416-23. PubMed ID: 22320241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.